Agaricus Mushroom

Agaricus subrufescens extracts have demonstrated antihypertensive and cardioprotective properties in animal studies (clinical trials in humans are reported for Agaricus blazei Murrill for antihypertensive effects). Potential additive blood pressure-lowering effects with antihypertensive medications.

Monitor blood pressure when adding Agaricus supplementation to an antihypertensive regimen. Dose adjustment is unlikely to be required at standard Agaricus doses but is possible in sensitive individuals.

Agaricus subrufescens (blazei) extract reduces insulin resistance via increased plasma adiponectin concentrations, improving insulin sensitivity in clinical studies. A clinical trial in type 2 diabetic patients taking oral antidiabetic agents reported hypoglycemia in 3 of 72 subjects receiving Agaricus extract 500 mg three times daily, indicating additive blood glucose-lowering activity.

Monitor blood glucose closely when combining Agaricus mushroom with antidiabetic drugs, particularly insulin and sulfonylureas. Educate patients about hypoglycemia symptoms. Discontinue at least 2 weeks before surgery due to hypoglycemia risk in the perioperative period.

Beta-glucans and polysaccharides in Agaricus subrufescens (riboglucans, glucomannans) potently stimulate NK cell cytotoxicity, macrophage activation, and Th1 cytokine production (IL-2, IFN-γ, TNF-α). These immunostimulatory effects may directly counteract immunosuppressant drugs used in organ transplant recipients and autoimmune conditions, potentially triggering rejection or disease flares.

Contraindicated in solid organ transplant recipients on immunosuppressive therapy. Avoid in patients with autoimmune conditions receiving azathioprine or mycophenolate. Disclose all mushroom supplement use to transplant physicians.

Beta-glucans and polysaccharides from Agaricus subrufescens enhance NK cell cytotoxicity and modulate T-cell activity. A phase I clinical study showed Agaricus extract (1800-5400 mg/day) was tolerated in cancer patients receiving chemotherapy and potentially improved NK cell activity and reduced chemotherapy-associated immunosuppression. Synergistic anti-tumour effects are biologically plausible but not consistently demonstrated in controlled trials.

Agaricus supplementation during chemotherapy should only occur under oncology team supervision. Coordinate timing relative to chemotherapy cycles. Document use in the medical record for interaction screening. Monitor haematological parameters.

Polysaccharides from Agaricus subrufescens may possess mild antiplatelet properties. Combined with anticoagulants or antiplatelet drugs, additive bleeding risk may occur. Additionally, any hepatotoxicity from Agaricus (reported in isolated case reports) could impair hepatic synthesis of clotting factors and potentiate warfarin.

Monitor for increased bleeding tendency in patients on anticoagulants or antiplatelet drugs who use Agaricus supplements. Report unusual bruising or prolonged bleeding to the prescriber. Avoid in patients with hepatic impairment.

In vitro, Agaricus blazei extract inhibits CYP3A4 with an IC50 of 1324 μg/mL (Engdal & Nilsen 2009). Although this IC50 is high relative to potent pharmacological inhibitors, suggesting low clinical significance at standard oral doses, narrow-therapeutic-index CYP3A4 substrates (simvastatin, midazolam, vincristine) may experience modest increases in plasma levels, particularly at high herbal extract doses.

Monitor patients on narrow-TI CYP3A4 substrates (e.g., simvastatin, midazolam, vincristine) when using Agaricus supplements. The risk is likely low at normal culinary doses but may increase with high-concentration extracts. In oncology settings, disclose all herbal supplement use to the oncologist.

Case reports document severe hepatic dysfunction, including fulminant hepatitis, in cancer patients taking Agaricus blazei extract (Mukai et al. 2006), with two deaths attributed in part to this supplement. Additional cases of drug-induced liver injury with histological features similar to autoimmune hepatitis have been reported (Katoh et al. 2015). Co-administration with inherently hepatotoxic medications (isoniazid, methotrexate, ketoconazole, valproate) compounds this hepatotoxicity risk.

Avoid concurrent use of Agaricus supplements with known hepatotoxic drugs. If use is unavoidable, obtain baseline LFTs and monitor monthly. Discontinue Agaricus immediately if transaminases exceed 3x ULN. Educate cancer patients about hepatic risk, as Agaricus is widely used in this population.

In vitro studies demonstrate that Agaricus blazei mycelia-dikaryon extract has estrogen-like activity and can activate estrogen receptor-mediated signaling pathways (Dong S et al. 2011). This estrogenic activity could potentially antagonize anti-estrogen therapies such as tamoxifen or aromatase inhibitors (anastrozole, letrozole) used in hormone-receptor-positive breast cancer, or could amplify the effects of exogenous estrogens (HRT, OCPs).

Patients with hormone-sensitive cancers (ER+ breast, uterine) receiving anti-estrogen treatment should avoid Agaricus supplementation. Inform patients on HRT or oral contraceptives about this potential estrogenic interaction. Oncologist consultation is mandatory before use in hormone-sensitive cancer patients.

Agaricus subrufescens beta-glucan polysaccharides are potent immunostimulants that activate NK cells, monocytes, dendritic cells, and shift Th1/Th2 cytokine balance. Co-administration with immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4 agents) could unpredictably amplify immune activation, potentially increasing risk of immune-related adverse events (irAEs) such as immune-mediated colitis, pneumonitis, hepatitis, or endocrinopathies.

Cancer patients undergoing immune checkpoint inhibitor therapy or biological immunotherapy should disclose Agaricus use to their oncologist. The combined immunostimulant effect is poorly understood and potentially harmful. Suspend Agaricus use during active immunotherapy until more safety data is available.